524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Year: 2021
Type: article
Source: Annals of Oncology
Authors: M.L. Johnson, E. Gort, S. Pant, M.P. Lolkema, M. Sebastian, M. Scheffler, J. Hwang, U. Dünzinger, K. Riemann, T. Kitzing, P.A. Jänne
Institutions: Sarah Cannon, Tennessee Oncology, University Medical Center Utrecht, The University of Texas MD Anderson Cancer Center, Erasmus MC Cancer Institute, University Hospital Frankfurt, University Hospital Cologne, Levine Cancer Institute, Boehringer Ingelheim (Germany), Dana-Farber Cancer Institute
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funder: Boehringer Ingelheim
OpenAlex ID: W3204964496